PCSK9 and coronary artery disorder: On the other hand, it exerts anti-inflammation effects by reducing LDL-C levels and LDL-R mediated platelet activation.50 51 Both can reduce the risk of MACEs in patients with CHD, and both are safe and well tolerated by the patients.52–54 In addition, PCSK9 inhibitors have a synergistic effect with statins.